{"id":"W2134009713","doi":"10.1136/annrheumdis-2013-204231","title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","year":2013,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":468,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"UCB Pharma; Genentech; Ablynx; Celgene; Biogen; National Center for Advancing Translational Sciences; Chugai Pharmaceutical; Celltrion; Synarc; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Certolizumab pegol; Ankylosing spondylitis; BASDAI; Placebo; BASFI; Axial spondyloarthritis; Internal medicine; Clinical endpoint; Adverse effect; Spondylitis; Physical therapy; Randomized controlled trial; Arthritis; Etanercept; Sacroiliitis; Rheumatoid arthritis; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002899562,0.0003768037,0.002043463,0.0002896168,0.000149837,0.00002181772,0.0002220238,0.00007221532,0.0001611772],"category_scores_gemma":[0.001698027,0.0002547212,0.0005837469,0.0003370209,0.0004217946,0.0001446883,0.0001734881,0.0001099268,0.000002862721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002162329,"about_ca_system_score_gemma":0.0001278636,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005583278,"about_ca_topic_score_gemma":0.00001583468,"domain_scores_codex":[0.9964882,0.0003129158,0.001686001,0.0003799754,0.0007660838,0.0003668062],"domain_scores_gemma":[0.9957245,0.001700507,0.001232021,0.0006929927,0.0004424263,0.0002075591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9334505,0.01775985,0.003022739,0.0009260124,0.003887898,0.00007441687,0.004310972,0.00002956348,0.0009446731,0.0001404949,0.0002915733,0.03516134],"study_design_scores_gemma":[0.9547285,0.01326541,0.01660753,0.005777731,0.001721706,0.00004640495,0.002293476,0.000149954,0.004862247,0.0002776491,0.00001096674,0.0002583922],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884124,0.003206807,0.000002400888,0.0004534592,0.0001360985,0.006574174,0.0007303797,0.0000215443,0.0004626912],"genre_scores_gemma":[0.9990965,0.0003667843,0.00003168959,0.00002040864,0.00003178844,0.0002807908,0.00005165627,0.00003478448,0.00008564306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03490295,"threshold_uncertainty_score":0.9999905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0739254593812622,"score_gpt":0.3478465486476314,"score_spread":0.2739210892663692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}